On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has swung higher to the tune of almost 8%. Interestingly, Friday’s afterhours ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

What Happened? A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation ...

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why BIIB stock is a hold.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with Eisai (ESALF). Read more here.

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Nearly 40% of Biogen investors said they want a CEO with a track record of successful business development, either through in-licensing deals or acquisitions, an RBC Capital Markets survey shows.

Biogen's quarterly revenue fell 6%, in part due to lower sales of the company's multiple sclerosis drugs in the U.S. due to cheaper, generic competition.

The biotechnology pioneer now expects revenue to be flat at constant currency versus last year. It previously forecast a mid-single digit decline. The company also expects adjusted earnings per-share ...